Suresh S Ramalingam

Summary

Affiliation: Emory University
Country: USA

Publications

  1. ncbi Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
    Suresh S Ramalingam
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 13:3605-10. 2007
  2. ncbi Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database
    Taofeek K Owonikoko
    Emory Winship Cancer Institute, 1365 Clifton Rd, Ste C 5090, Atlanta, GA 30322, USA
    J Clin Oncol 25:5570-7. 2007
  3. ncbi Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer
    Suresh S Ramalingam
    Winship Cancer Institute, Emory University, 1365 Clifton Rd NE, Suite C 3090, Atlanta, GA 30322, USA
    J Clin Oncol 30:3337-44. 2012
  4. ncbi Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Thorac Oncol 5:1279-84. 2010
  5. ncbi Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study
    Suresh S Ramalingam
    Emory University, Winship Cancer Institute, Atlanta, GA 30322, USA
    J Clin Oncol 28:4507-12. 2010
  6. ncbi Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer
    Suresh S Ramalingam
    Emory University, Winship Cancer Institute, 1365 Clifton Rd, C 3090, Atlanta, GA 30322, USA
    J Clin Oncol 28:56-62. 2010
  7. ncbi Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504)
    Suresh S Ramalingam
    Emory University, Winship Cancer Institute, Atlanta, GA, USA
    J Clin Oncol 29:1709-14. 2011
  8. ncbi Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003)
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA
    J Thorac Oncol 6:1741-5. 2011
  9. ncbi The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Oncologist 14:412-24. 2009
  10. ncbi Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA
    J Thorac Oncol 4:97-101. 2009

Detail Information

Publications48

  1. ncbi Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
    Suresh S Ramalingam
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 13:3605-10. 2007
    ..The primary objective of this study was to determine the recommended phase II doses of the novel histone deacetylase inhibitor vorinostat when administered in combination with carboplatin and paclitaxel...
  2. ncbi Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database
    Taofeek K Owonikoko
    Emory Winship Cancer Institute, 1365 Clifton Rd, Ste C 5090, Atlanta, GA 30322, USA
    J Clin Oncol 25:5570-7. 2007
    ..To study the burden and outcome of lung cancer in the elderly, particularly for patients aged 80 years and older...
  3. ncbi Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer
    Suresh S Ramalingam
    Winship Cancer Institute, Emory University, 1365 Clifton Rd NE, Suite C 3090, Atlanta, GA 30322, USA
    J Clin Oncol 30:3337-44. 2012
    ....
  4. ncbi Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097)
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Thorac Oncol 5:1279-84. 2010
    ..We evaluated the safety and efficacy of cediranib, a potent small molecule inhibitor of the vascular endothelial growth factor receptor, in patients with refractory or recurrent small cell lung cancer (SCLC)...
  5. ncbi Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study
    Suresh S Ramalingam
    Emory University, Winship Cancer Institute, Atlanta, GA 30322, USA
    J Clin Oncol 28:4507-12. 2010
    ..We conducted a phase I study to determine the maximum-tolerated dose and pharmacokinetics of vorinostat in patients with hepatic dysfunction...
  6. ncbi Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer
    Suresh S Ramalingam
    Emory University, Winship Cancer Institute, 1365 Clifton Rd, C 3090, Atlanta, GA 30322, USA
    J Clin Oncol 28:56-62. 2010
    ..CONCLUSION Vorinostat enhances the efficacy of carboplatin and paclitaxel in patients with advanced NSCLC. HDAC inhibition is a promising therapeutic strategy for treatment of NSCLC...
  7. ncbi Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504)
    Suresh S Ramalingam
    Emory University, Winship Cancer Institute, Atlanta, GA, USA
    J Clin Oncol 29:1709-14. 2011
    ..We conducted a phase II study to evaluate cetuximab for the treatment of advanced BAC...
  8. ncbi Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003)
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA
    J Thorac Oncol 6:1741-5. 2011
    ..Bortezomib, a proteasome inhibitor, has demonstrated objective responses in patients with BAC in early-phase clinical trials. We conducted a phase II study of bortezomib in patients with advanced-stage BAC...
  9. ncbi The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Oncologist 14:412-24. 2009
    ..In addition to the available evidence, prospective evaluation of novel agents in elderly-specific or -enriched studies is necessary to guide the treatment of older patients with NSCLC...
  10. ncbi Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA
    J Thorac Oncol 4:97-101. 2009
    ..This class of compounds has demonstrated anticancer activity in malignant mesothelioma. We conducted a phase II study of belinostat in patients with relapsed malignant pleural mesothelioma...
  11. ncbi Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer
    Suresh S Ramalingam
    Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
    J Clin Oncol 29:4574-80. 2011
    ..The strong preclinical evidence supporting coinhibition of IGF-1R and epidermal growth factor receptor (EGFR) as anticancer therapy prompted this study...
  12. ncbi Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599
    Suresh S Ramalingam
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA
    J Clin Oncol 26:60-5. 2008
    ..We conducted a subset analysis of ECOG 4599 to determine the outcome for elderly patients...
  13. ncbi A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies
    Suresh S Ramalingam
    Authors Affiliations Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Clin Cancer Res 14:3456-61. 2008
    ..We conducted a phase I study in patients with advanced malignancies to determine the recommended phase II dose of the combination of 17-AAG and paclitaxel...
  14. ncbi The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo
    Hui Ren
    Department of Respiration, First Affiliated Hospital of Medical College of Xi an Jiaotong University, Shaanxi, PR China
    Cancer Lett 325:139-46. 2012
    ..Collectively, we suggest that the combination of RAD001 and BKM120 may be an effective regimen for treatment of lung cancer, hence warranting further evaluation of the combination in the clinic...
  15. ncbi Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells
    Taofeek K Owonikoko
    University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Int J Cancer 126:743-55. 2010
    ..This likely involves a vorinostat-mediated irreversible increase in DNA damage in the case of carboplatin and a reversible increase in microtubule stability in the case of paclitaxel...
  16. ncbi Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia 30322, USA
    Cancer 116:3903-9. 2010
    ..The authors conducted a phase 1 and pharmacokinetic study of everolimus and docetaxel for recurrent NSCLC...
  17. ncbi Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy
    Cheng Xiong Xu
    Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA
    Cancer Biol Ther 12:549-55. 2011
    ..Thus, induction of autophagy by BEZ235 appears to be a survival mechanism that may counteract its anticancer effects. Based on these, we suggest a strategy to enhance BEZ235's anticancer efficacy by blockade of autophagy...
  18. ncbi Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study
    Chandra P Belani
    Department of Medicine, Penn State Hershey Medical Center, Penn State Cancer Institute, Hershey, Pennsylvania 17033 0850, USA
    Cancer 113:2512-7. 2008
    ..Therefore, a phase 2 study was conducted to evaluate the efficacy of the combination of cetuximab, carboplatin, and docetaxel for the treatment of advanced NSCLC...
  19. ncbi A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer
    Taofeek K Owonikoko
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA
    J Thorac Oncol 7:866-72. 2012
    ..Potential differences in the efficacy of second-line therapy for refractory and sensitive SCLC have not been well studied...
  20. ncbi Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors
    Ramesh K Ramanathan
    Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Clin Oncol 28:1520-6. 2010
    ..To define the maximum tolerated dose, toxicities, pharmacokinetics, and pharmacodynamics of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG)...
  21. ncbi Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer
    Yikun Li
    Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, USA
    Cancer Biol Ther 13:272-80. 2012
    ..Taken together, we suggest that elevated eIF4E in NSCLC cells is associated with proliferation, invasion and acquired erlotinib resistance...
  22. ncbi A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA
    Hum Gene Ther 22:336-42. 2011
    ..There were no dose-limiting toxicities reported in all three dosing tiers. It is concluded that the oral administration of MnSOD PL is feasible and safe. The phase II recommended dose is 30 mg...
  23. ncbi Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus
    Taofeek K Owonikoko
    Emory University Winship Cancer Institute, Atlanta, Georgia, USA
    Clin Cancer Res 16:2496-504. 2010
    ..This article reviews recent data with maintenance therapy in advanced NSCLC and discusses the implications for routine patient care and future drug development...
  24. ncbi The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo
    Cheng Xiong Xu
    Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, Georgia, United States of America
    PLoS ONE 6:e20899. 2011
    ..Taken together, our results suggest that the combination of RAD001 and BEZ235 is a novel strategy for cancer therapy...
  25. ncbi Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women
    Seema Harichand-Herdt
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA 30322, USA
    Semin Oncol 36:572-80. 2009
    ..This article reviews the gender-related differences in clinical and pathologic factors and outcomes of patients with lung cancer observed in population-based studies and clinical trials...
  26. ncbi Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor
    Seema Harichand-Herdt
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA
    Semin Thorac Cardiovasc Surg 20:217-23. 2008
    ..This article reviews the role of currently available and emerging EGFR inhibitors in the treatment of NSCLC...
  27. ncbi Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies
    John Kauh
    Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, Georgia, USA
    Cancer 117:4049-59. 2011
    ..This pilot study evaluated the biological effects of LNF and docetaxel (DTX) combination therapy in refractory solid tumors by comparing pretreatment and post-treatment tumor biopsies...
  28. ncbi Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy
    Xuerong Wang
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Cancer Biol Ther 7:1952-8. 2008
    ..Thus, we suggest a therapeutic strategy for enhancing mTOR-targeted cancer therapy by preventing mTOR inhibition-induced feedback activation of several survival mechanisms...
  29. ncbi Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis
    Madhusmita Behera
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, Atlanta, GA, USA
    Lung Cancer 77:331-8. 2012
    ..Maintenance therapy is a new treatment paradigm for advanced non-small cell lung cancer (NSCLC). We conducted a meta-analysis of randomized studies with single agent maintenance therapy...
  30. ncbi Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer
    Taofeek K Owonikoko
    Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia
    Cancer 119:1503-11. 2013
    ..For this study, the authors assessed the association of cellular-based and serum-based immunologic mediators with thyroid cancer recurrence...
  31. ncbi Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy
    Suchita Pakkala
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA 30322, USA
    Clin Lung Cancer 10:S17-23. 2009
    ..Another novel agent, XL647, has demonstrated promising single-agent activity in patients who have been resistant to previous anti-EGFR therapy. Further evaluation of combined EGFR and VEGF inhibition is under investigation...
  32. ncbi Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues
    Songqing Fan
    Department of Hematology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
    Cancer Biol Ther 8:1463-9. 2009
    ..05). Collectively, these findings suggest that p-eIF4E may play a critical role in cancer development, particularly early stages of tumorigenesis and support p-eIF4E as a good cancer therapeutic target...
  33. ncbi Lung cancer: New biological insights and recent therapeutic advances
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA
    CA Cancer J Clin 61:91-112. 2011
    ..This article reviews the major strides made in the treatment of lung cancer in the recent past...
  34. ncbi Survival analysis of patients with stage I non-small-cell lung cancer using clinical and DNA repair pathway expression variables
    Madhusmita Behera
    Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
    Clin Lung Cancer 14:128-38. 2013
    ..Lung cancer is the leading cause of cancer-related mortality. Understanding patient attributes that enhance survival and predict recurrence is necessary to individualize treatment options...
  35. ncbi Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Emory University, Winship Cancer Institute, 1365 Clifton Road NE, Atlanta, GA 30322, USA
    J Thorac Oncol 8:369-72. 2013
    ..01) but not with progression-free survival or overall survival. The combination of everolimus and docetaxel was tolerated well, but the efficacy was relatively modest in an unselected population of patients with NSCLC...
  36. ncbi Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy
    Suchita Pakkala
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, USA
    Cancer 118:164-72. 2012
    ..Because highly active antiretroviral therapy (HAART) has improved the survival of patients with human immunodeficiency virus (HIV), the authors evaluated lung cancer outcomes in the HAART era...
  37. ncbi Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer
    Suresh S Ramalingam
    Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA
    Cancer 116:1344-9. 2010
    ..Irinotecan and paclitaxel are active as single agents and exhibit preclinical synergy in SCLC cell lines. A phase 2 study was conducted to evaluate this combination in patients with recurrent or refractory SCLC...
  38. ncbi The role of cetuximab in the management of non-small-cell lung cancer
    Taofeek K Owonikoko
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA 30322, USA
    Clin Lung Cancer 10:230-8. 2009
    ..This article reviews the clinical data with cetuximab in NSCLC...
  39. ncbi c-Myc Suppression of DNA Double-strand Break Repair
    Zhaozhong Li
    Department of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, GA
    Neoplasia 14:1190-202. 2012
    ....
  40. ncbi Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer data
    Madhusmita Behera
    Department of Hematology and Medical Oncology, Emory University, Winship Cancer Institute, 1365 Clifton Road NE, Rm C 3090, Atlanta, GA 30322, USA
    Biomed Eng Online 10:97. 2011
    ..Statistical learning (SL) techniques can address non-linear relationships and small datasets but do not provide an output that has an epidemiologic interpretation...
  41. ncbi Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope
    Suresh S Ramalingam
    Emory University, Winship Cancer Institute, Atlanta, Georgia, USA
    Curr Opin Oncol 22:79-85. 2010
    ..This review will provide the relevant interventions targeted against specific angiogenesis pathways with or without known effective therapies for nonsmall cell lung cancer (NSCLC)...
  42. ncbi Retinoic acid enhances TRAIL-induced apoptosis in cancer cells by upregulating TRAIL receptor 1 expression
    Latha Dhandapani
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA
    Cancer Res 71:5245-54. 2011
    ..Taken together, our findings establish that ATRA accentuates TRAIL-induced apoptosis, reveal a novel mechanism by which retinoids modulate apoptosis, and suggest a novel strategy to augment the anti-cancer activity of TRAIL...
  43. ncbi Recent advances in the treatment of malignant pleural mesothelioma
    Suresh S Ramalingam
    Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, USA
    J Thorac Oncol 3:1056-64. 2008
    ..It is hoped that the HDAC inhibitors and other novel targeted agents will pave the way for improved outcomes for patients with this disease...
  44. ncbi The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation
    Rathi N Pillai
    Department of Hematology and Medical Oncology, Emory University, Atlanta, GA 30322, USA
    Curr Oncol Rep 14:105-10. 2012
    ..This article reviews the characteristics, treatment, and ongoing research in patients with ALK-positive NSCLC...
  45. ncbi Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases
    Qi Qi
    Department of Pathology and Laboratory Medicine, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Biol Chem 287:6113-27. 2012
    ..Hence, combinatorial inhibition of EGFR and PKCs might provide proof of concept in developing therapeutic agents for treating malignant glioma and other human cancers...
  46. ncbi Lung cancer in HIV-positive patients
    Suchita Pakkala
    Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, USA
    J Thorac Oncol 5:1864-71. 2010
    ..This article reviews the impact of HIV on the incidence, risk factors, clinical presentation, and treatment of lung cancer...
  47. ncbi CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC
    Rathi N Pillai
    Department of Hematology and Oncology, Emory University, Atlanta, Georgia 30322, USA
    Clin Cancer Res 19:1603-11. 2013
    ..Results were validated in an additional 20 patients who received taxane-based chemotherapy at Emory University Hospital and the Atlanta VAMC...
  48. ncbi Monoclonal antibodies versus tyrosine kinase inhibitors concurrent with chemotherapy in non-small-cell lung cancer: exploring divergent results
    Primo N Lara
    Clin Lung Cancer 9:141-3. 2008